Zevra Therapeutics (ZVRA) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Document Information [Line Items]
Entity Central Index Key	0001434647
Entity Registrant Name	KEMPHARM, INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36913
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5894398
Entity Address, Address Line One	1180 Celebration Boulevard, Suite 103
Entity Address, City or Town	Celebration
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34747
City Area Code	321
Local Phone Number	939-3416
Title of 12(b) Security	Common
Trading Symbol	KMPH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,319,426

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 131,503	$ 4,213
Accounts and other receivables	1,619	2,579
Prepaid expenses and other current assets	1,508	1,481
Restricted cash	0	109
Total current assets	134,630	8,382
Property and equipment, net	931	1,039
Operating lease right-of-use assets	1,186	1,350
Other long-term assets	439	438
Total assets	137,186	11,209
Liabilities and stockholders' equity (deficit)
Accounts payable and accrued expenses	2,085	6,647
Current portion of operating lease liabilities	349	327
Current portion of loans payable	0	390
Other current liabilities	1,264	172
Total current liabilities	3,698	7,536
Convertible notes, less current portion, net	0	67,658
Derivative and warrant liability	396	304
Operating lease liabilities, less current portion	1,324	1,587
Loans payable	0	391
Other long-term liabilities	31	145
Total liabilities	5,449	77,621
Commitments and contingencies (Note D)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value, 250,000,000 shares authorized, 35,317,313 shares issued and outstanding as of September 30, 2021; 4,537,321 shares issued and outstanding as of December 31, 2020	4	0
Additional paid-in capital	396,059	192,062
Accumulated deficit	(264,326)	(258,474)
Total stockholders' equity (deficit)	131,737	(66,412)
Total liabilities and stockholders' equity (deficit)	137,186	11,209
Undesignated Preferred Stock [Member]
Stockholders’ equity (deficit):
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2021; 9,961,846 shares authorized, no shares issued or outstanding as of December 31, 2020	$ 0	$ 0

Condensed Balance Sheets (Cur_2

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0
Preferred stock, shares outstanding (in shares)	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	35,317,313	4,537,321
Common stock, shares outstanding (in shares)	35,317,313	4,537,321
Undesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	9,961,846
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 1,965	$ 1,925	$ 26,068	$ 10,922
Operating expenses:
Royalty and direct contract acquisition costs	0	0	2,000	1,305
Research and development	2,239	1,709	7,352	5,789
General and administrative	1,948	1,429	6,145	5,393
Severance expense	0	0	0	830
Total operating expenses	4,187	3,138	15,497	13,317
(Loss) income from operations	(2,222)	(1,213)	10,571	(2,395)
Other income (expense):
Loss on extinguishment of debt	0	0	(16,096)	0
Interest expense related to amortization of debt issuance costs and discount	0	(578)	(150)	(1,723)
Interest expense on principal	(6)	(1,163)	(221)	(3,620)
Fair value adjustment related to derivative and warrant liability	332	(137)	(92)	(65)
Interest and other income (expense), net	137	48	136	(135)
Total other income (expense)	463	(1,830)	(16,423)	(5,543)
Loss before income taxes	(1,759)	(3,043)	(5,852)	(7,938)
Income tax benefit	0	34	0	34
Net income (loss)	(1,759)	(3,009)	(5,852)	(7,904)
Deemed dividend	0	0	(54,342)	0
Net loss attributable to common stockholders	$ (1,759)	$ (3,009)	$ (60,194)	$ (7,904)
Basic net loss per share of common stock:
Net loss (in dollars per share)	$ (0.05)	$ (0.68)	$ (0.21)	$ (2.08)
Net loss attributable to common stockholders (in dollars per share)	(0.05)	(0.68)	(2.16)	(2.08)
Diluted net loss per share of common stock:
Net loss attributable to common stockholders (in dollars per share)	$ (0.06)	$ (0.68)	$ (2.16)	$ (2.08)
Weighted average number of shares of common stock outstanding:
Basic (in shares)	35,217,953	4,425,474	27,904,711	3,794,840
Diluted (in shares)	35,217,953	4,425,474	27,904,711	3,794,840

Unaudited Condensed Statement_2

Unaudited Condensed Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Underwritten Public Offering [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Underwritten Public Offering [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Underwritten Public Offering [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Underwritten Public Offering [Member]Undesignated Preferred Stock [Member]	Underwritten Public Offering [Member]Common Stock [Member]	Underwritten Public Offering [Member]Additional Paid-in Capital [Member]	Underwritten Public Offering [Member]Retained Earnings [Member]	Underwritten Public Offering [Member]	Equity Line of Credit [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Equity Line of Credit [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Equity Line of Credit [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Equity Line of Credit [Member]Undesignated Preferred Stock [Member]	Equity Line of Credit [Member]Common Stock [Member]	Equity Line of Credit [Member]Additional Paid-in Capital [Member]	Equity Line of Credit [Member]Retained Earnings [Member]	Equity Line of Credit [Member]	Optional Exchange Principal Amount [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Optional Exchange Principal Amount [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Optional Exchange Principal Amount [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Optional Exchange Principal Amount [Member]Undesignated Preferred Stock [Member]	Optional Exchange Principal Amount [Member]Common Stock [Member]	Optional Exchange Principal Amount [Member]Additional Paid-in Capital [Member]	Optional Exchange Principal Amount [Member]Retained Earnings [Member]	Optional Exchange Principal Amount [Member]	January 2021 Inducement Warrants [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	January 2021 Inducement Warrants [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	January 2021 Inducement Warrants [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	January 2021 Inducement Warrants [Member]Undesignated Preferred Stock [Member]	January 2021 Inducement Warrants [Member]Common Stock [Member]	January 2021 Inducement Warrants [Member]Additional Paid-in Capital [Member]	January 2021 Inducement Warrants [Member]Retained Earnings [Member]	January 2021 Inducement Warrants [Member]	Warrants to Purchase Common Stock [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Warrants to Purchase Common Stock [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Warrants to Purchase Common Stock [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Warrants to Purchase Common Stock [Member]Undesignated Preferred Stock [Member]	Warrants to Purchase Common Stock [Member]Common Stock [Member]	Warrants to Purchase Common Stock [Member]Additional Paid-in Capital [Member]	Warrants to Purchase Common Stock [Member]Retained Earnings [Member]	Warrants to Purchase Common Stock [Member]	Exchange Warrants [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Exchange Warrants [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Exchange Warrants [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Exchange Warrants [Member]Undesignated Preferred Stock [Member]	Exchange Warrants [Member]Common Stock [Member]	Exchange Warrants [Member]Additional Paid-in Capital [Member]	Exchange Warrants [Member]Retained Earnings [Member]	Exchange Warrants [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Undesignated Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Common Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Additional Paid-in Capital [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]Retained Earnings [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Undesignated Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]Retained Earnings [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]	Preferred Stock [Member]Series A Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B-1 Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B-2 Convertible Preferred Stock [Member]	Undesignated Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019																																																																	$ 0	$ 0	$ 0	$ 0	$ 0	$ 171,258	$ (245,714)	$ (74,456)
Net income (loss)																																																																	0	0	0	0	0	0	(5,754)	(5,754)
Stock-based compensation expense																																																																	0	0	0	0	0	1,029	0	1,029
Issuance of common stock in connection with Public Offering, net of discounts and commissions									$ 0	$ 0	$ 0	$ 0	$ 0	$ 1,112	$ 0	$ 1,112	$ 0	$ 0	$ 0	$ 0	$ 0	$ 9,600	$ 0	$ 9,600
Offering expenses charged to equity																																																																	0	0	0	0	0	(327)	0	(327)
Change in estimated deferred offering costs									0	0	0	0	0	121	0	121
Balance at Mar. 31, 2020																																																																	0	0	0	0	0	182,793	(251,468)	(68,675)
Balance at Dec. 31, 2019																																																																	0	0	0	0	0	171,258	(245,714)	(74,456)
Net income (loss)																																																																								(7,904)
Balance at Sep. 30, 2020																																																																	0	0	0	0	0	191,291	(253,618)	(62,327)
Balance at Mar. 31, 2020																																																																	0	0	0	0	0	182,793	(251,468)	(68,675)
Net income (loss)																																																																	0	0	0	0	0	0	859	859
Stock-based compensation expense																																																																	0	0	0	0	0	620	0	620
Issuance of common stock in connection with Public Offering, net of discounts and commissions									$ 0	$ 0	$ 0	$ 0	$ 0	$ 1,191	$ 0	$ 1,191	0	0	0	0	0	3,150	0	3,150
Offering expenses charged to equity																																																																	0	0	0	0	0	(92)	0	(92)
Issuance of common stock in exchange for consulting services																																																																	0	0	0	0	0	84	0	84
Balance at Jun. 30, 2020																																																																	0	0	0	0	0	187,746	(250,609)	(62,863)
Net income (loss)																																																																	0	0	0	0	0	0	(3,009)	(3,009)
Stock-based compensation expense																																																																	0	0	0	0	0	385	0	385
Issuance of common stock in connection with Public Offering, net of discounts and commissions																	$ 0	$ 0	$ 0	$ 0	$ 0	$ 3,113	$ 0	$ 3,113
Issuance of common stock in exchange for consulting services																																																																	0	0	0	0	0	47	0	47
Balance at Sep. 30, 2020																																																																	0	0	0	0	0	191,291	(253,618)	(62,327)
Balance at Dec. 31, 2020																																																																	0	0	0	0	0	192,062	(258,474)	(66,412)
Net income (loss)																																																																	0	0	0	0	0	0	(10,296)	(10,296)
Stock-based compensation expense																																																																	0	0	0	0	0	675	0	675
Issuance of common stock in connection with Public Offering, net of discounts and commissions	$ 0	$ 0	$ 0	$ 0	$ 1	$ 49,284	$ 0	$ 49,285
Issuance of common stock in connection with the exercise of warrants																									$ 0	$ 0	$ 0	$ 0	$ 1	$ 40,390	$ 0	$ 40,391	$ 0	$ 0	$ 0	$ 0	$ 0	$ 25,593	$ 0	$ 25,593
Fair value of warrants issued																									0	0	0	0	0	38,437	0	38,437									$ 0	$ 0	$ 0	$ 0	$ 0	$ 15,990	$ 0	$ 15,990
Issuance of stock as a result of conversion																																																	$ 0	$ 0	$ 29,056	$ 0	$ 0	$ 0	$ 0	$ 29,056	$ 0	$ 0	$ (29,056)	$ 0	$ 1	$ 29,055	$ 0	$ 0
Deemed dividend related the Inducement Transaction																																																																	0	0	0	0	0	(37,444)	0	(37,444)
Offering expenses charged to equity																																																																	0	0	0	0	0	(1,106)	0	(1,106)
Issuance of common stock in exchange for consulting services																																																																	0	0	0	0	0	82	0	82
Balance at Mar. 31, 2021																																																																	0	0	0	0	3	353,018	(268,770)	84,251
Balance at Dec. 31, 2020																																																																	0	0	0	0	0	192,062	(258,474)	(66,412)
Net income (loss)																																																																								(5,852)
Balance at Sep. 30, 2021																																																																	0	0	0	0	4	396,059	(264,326)	131,737
Balance at Mar. 31, 2021																																																																	0	0	0	0	3	353,018	(268,770)	84,251
Net income (loss)																																																																	0	0	0	0	0	0	6,203	6,203
Stock-based compensation expense																																																																	0	0	0	0	0	318	0	318
Issuance of common stock in connection with the exercise of warrants																									0	0	0	0	0	35,455	0	35,455	0	0	0	0	0	4,191	0	4,191
Fair value of warrants issued																																																																	0	0	0	0	0	17,089		17,089
Deemed dividend related the Inducement Transaction																																																																	0	0	0	0	0	(16,898)		(16,898)
Offering expenses charged to equity																																																																	0	0	0	0	0	(18)	0	(18)
Issuance of common stock in exchange for consulting services																																																																	0	0	0	0	0	72	0	72
Balance at Jun. 30, 2021																																																																	0	0	0	0	3	393,227	(262,567)	130,663
Net income (loss)																																																																	0	0	0	0	0	0	(1,759)	(1,759)
Stock-based compensation expense																																																																	0	0	0	0	0	620	0	620
Issuance of common stock in connection with the exercise of warrants																									$ 0	$ 0	$ 0	$ 0	$ 1	$ 1,104	$ 0	$ 1,105	$ 0	$ 0	$ 0	$ 0	$ 0	$ 1,035	$ 0	$ 1,035
Issuance of common stock in exchange for consulting services																																																																	0	0	0	0	0	73	0	73
Balance at Sep. 30, 2021																																																																	$ 0	$ 0	$ 0	$ 0	$ 4	$ 396,059	$ (264,326)	$ 131,737

Unaudited Condensed Statement_3

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended	21 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Sep. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ (1,759)	$ (10,296)	$ (3,009)	$ (5,754)	$ (5,852)	$ (7,904)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt	0		0		16,096	0
Stock-based compensation expense					1,613	2,034
Non-cash interest expense					8	3,583
Amortization of debt issuance costs and debt discount	0		578		150	1,723
Depreciation and amortization expense					193	207
Fair value adjustment related to derivative and warrant liability	(332)		137		92	65
Change in estimated deferred offering costs					0	130
Loss on sublease and disposal of property and equipment					76	251
Consulting fees paid in common stock					227	131
Change in assets and liabilities:
Accounts and other receivables					960	(337)
Prepaid expenses and other assets					(1,366)	537
Operating lease right-of-use assets					88	121
Accounts payable and accrued expenses					(1,891)	(1,299)
Operating lease liabilities					(241)	(194)
Other liabilities					1,134	72
Net cash provided by (used in) operating activities					11,287	(880)
Cash flows from investing activities:
Purchases of property and equipment					(85)	(7)
Net cash used in investing activities					(85)	(7)
Cash flows from financing activities:
Proceeds from Public Offering, net of discounts and commissions					49,285	0
Proceeds from equity line of credit					0	2,303
Proceeds from Payment Protection Program loan					0	781
Payment of offering costs					(1,299)	(97)
Repayment of principal on finance lease liabilities					(156)	(168)
Payment of debt issuance costs					(2,881)	(34)
Repayment of principal on convertible notes					(37,924)	0
Net proceeds from exercise of common stock warrants					30,819	0
Net cash provided by financing activities					115,979	2,785
Net increase in cash, cash equivalents and restricted cash					127,181	1,898
Cash, cash equivalents and restricted cash, beginning of period		$ 4,322		$ 3,555	4,322	3,555	$ 3,555	$ 3,555
Cash, cash equivalents and restricted cash (2020), end of period	$ 131,503		$ 5,453		131,503	5,453	$ 4,322	$ 131,503
Supplemental cash flow information:
Cash paid for interest					213	71
Commitment shares issued in connection with equity line of credit included in deferred offering costs					0	121
Amounts due for property and equipment included in accounts payable and accrued expenses					0	4
Amounts due for deferred offering costs included in accounts payable and accrued expenses					70	0
Fair value of warrants issued to underwriters in connection with Public Offering					3,485	0
Conversion of Facility Notes into Series B-2 Preferred Stock [Member]
Supplemental cash flow information:
Notes principal converted					31,477	0
The 2019 Notes Converted to Common Stock [Member]
Supplemental cash flow information:
Notes principal converted					0	15,863
Warrants Issued in Connection with January 2021 Inducement Transaction [Member]
Cash flows from financing activities:
Proceeds from Inducement Transaction, net of discounts and commissions					41,384	0
Warrants Issued in Connection with June 2021 Inducement Transaction [Member]
Cash flows from financing activities:
Proceeds from Inducement Transaction, net of discounts and commissions					$ 36,751	$ 0

Note A - Description of Busines

Note A - Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	A. Description of Business and Basis of Presentation Organization KemPharm, Inc. (the “Company”) is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary Ligand Activated Therapy ("LAT") technology. The Company utilizes its proprietary LAT technology to generate improved prodrug versions of U.S. Food and Drug Administration (the "FDA") approved drugs as well as to generate prodrug versions of existing compounds that may KP415 six The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10 8 03 X. not three nine September 30, 2021 not may December 31, 2021. This interim information should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 10 December 31, 2020, March 12, 2021. Reverse Stock Split On December 23, 2020, one sixteen not No Entry into 2020 In February 2020, “2020 may 2020 2020 2020 2020 “2020 may 2020 3 May 2020, 19,289 2 2020 2020 May 2020, 19,289 2020 Underwriting Agreement On January 8, 2021, 1 No. 333 250945 On January 8, 2021, February 1, 2021, On January 12, 2021, Listing on the Nasdaq Capital Market On January 7, 2021, January 8, 2021 Entry into 2021 On July 2, 2021, "2021 may 2021 3. may 415 1933, may 2021 3 2021 July 12, 2021. September 30, 2021, 2021

Note B - Summary of Significant

Note B - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	B. Summary of Significant Accounting Policies Use of Estimates The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Revenue Recognition The Company commenced recognizing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers 606” January 1, 2018. Arrangements with Multiple-Performance Obligations From time to time, the Company enters into arrangements for research and development, manufacturing and/or commercialization services. Such arrangements may In arrangements involving more than one not The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not Licensing Agreements The Company enters into licensing agreements with licensees that fall under the scope of ASC 606. The terms of the Company’s licensing agreements typically include one may As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may Up-front Fees: Milestone Payments: not not not may KP415 In September 2019, “KP415 KP415 KP484, KP879, KP922 KP484, KP415 KP484; KP415 KP415 KP415 Commave also agreed to be responsible for and reimburse the Company for all of the development, commercialization and regulatory expenses incurred on the licensed products, subject to certain limitations as set forth in the KP415 The KP415 KP484. KP484; In accordance with the terms of the Company’s March 20, 2012 KP484, KP879 KP1077 KP415 The KP415 606, not KP415 606, third two $10.0 KP415 The consideration allocated to the grant of the exclusive, worldwide license was $10.0 KP415 KP415 The consideration allocated to the performance of consulting services, which includes the reimbursement of out-of-pocket third KP415 third third no third third third third 606 third third KP415 September 30, 2021, third Under the KP415 first 1 may may KP415 KP415 first not third 606 not not The Company is entitled to additional payments from Commave conditioned upon the achievement of specified regulatory milestones related to AZSTARYS and KP484 KP415 KP415 not not not For example, in May 2020, KP415 two second 2020 second 2020. In April 2021, No. 1 KP415 "KP415 KP415 KP415 KP415 KP415 March 2, 2021. May 7, 2021. KP415 KP415 Pursuant to the KP415 KP922, no Per the KP415 March 2021, May 2021. two first 2021 first second 2021, 340 40, Contracts with Customers first second 2021, For the three September 30, 2021, KP415 three September 30, 2020, KP415 nine September 30, 2021 2020, KP415 September 30, 2021 December 31, 2020. APADAZ License Agreement In October 2018, Pursuant to the APADAZ License Agreement, KVK agreed to pay the Company certain payments and cost reimbursements of an estimated $3.4 million, which includes a payment of $2.0 million within 10 four The APADAZ License Agreement will terminate on the later of the date that all of the patent rights for APADAZ have expired in the United States or KVK’s cessation of commercialization of APADAZ in the United States. KVK may 90 may 18 may six may 30 not The APADAZ License Agreement also established a joint steering committee, which monitors progress of the commercialization of APADAZ. Consulting Arrangements The Company enters into consulting arrangements with third 606. may third Corium Consulting Agreement In July 2020, KP415 Under the Corium Consulting Agreement, the Company is entitled to receive payments from Corium of up to $15.6 million, $13.6 million of which will be paid in quarterly installments through March 31, 2022. The Corium Consulting Agreement is within the scope of ASC 606, not 606, third third not not not The Company determined that the performance of consulting services, including reimbursement of third third 606 September 30, 2021, third For the three nine September 30, 2021, three nine September 30, 2020, September 30, 2021, December 31, 2020, Other Consulting Arrangements For the three September 30, 2021 2020, nine September 30, 2021 2020, September 30, 2021 December 31, 2020. Accounts and Other Receivables Accounts and other receivables consist of receivables under the KP415 KP415 third September 30, 2021, December 31, 2020, September 30, 2021, December 31, 2020, no Application of New or Revised Accounting Standards—Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 Measurement of Credit Losses on Financial Instruments 2016 13” not not December 15, 2019, 2016 13 not In August 2018, 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement 2018 13” 820, Conceptual Framework for Financial Reporting Chapter 8: August 28, 2018, December 15, 2019, 3 2018 13 not Application of New or Revised Accounting Standards—Not Yet Adopted In August 2020, 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815 40 Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06” December 15, 2021, not 2020 06 In May 2021, 2021 04, Earnings Per Share (Topic 260 470 50 718 815 40 2021 04” December 15, 2021, not 2021 04

Note C - Debt Obligations

Note C - Debt Obligations	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	C. Debt Obligations As of September 30, 2021 December 31, 2020, Deerfield Facility Agreement In June 2014, first December 2020, The Deerfield Convertible Note originally bore interest at 9.75% per annum, but was subsequently reduced to 6.75%. Interest accrued on the outstanding balance under the Deerfield Convertible Note was due quarterly in arrears. The Company originally had to repay one third fourth fifth June 2018 June 2019). June 2018, September 2019, June 1, 2020 “2021 September 2019”). December 2019, March 31, 2021 “2021 December 2019”). March 31, 2021. not Pursuant to the Deerfield Facility Agreement, the Company issued to Deerfield a warrant to purchase 14,423,076 shares of Series D Preferred at an initial exercise price of $0.78 per share, which is exercisable until June 2, 2024 December 2020, January 2021 June 2021 January 2021 June 2021 260, may The Company recorded the fair value of the shares of Series D Preferred to debt issuance costs on the date of issuance. The Company also recorded the fair value of the Deerfield Warrant and the embedded Warrant Put Option to debt discount on the date of issuance. The debt issuance costs and debt discount were amortized over the term of the related debt and the expense was recorded as interest expense related to amortization of debt issuance costs and discount in the unaudited condensed statements of operations. In the first 2021, 2 Pursuant to the Deerfield Facility Agreement, the Company was not Issuance of 5.50% Senior Convertible Notes and Third Amendment to Senior Secured Convertible Note and Warrant In February 2016, 2021 “2021 2021 144A 1933, The 2021 February 9, 2016 2021 February 1 August 1 August 1, 2016, 5.50% 2021 February 1, 2021 The net proceeds from the Note Offering were approximately $82.8 million, after deducting the Initial Purchasers’ discount and estimated offering expenses. Concurrent with the Note Offering, the Company used approximately $18.6 million of the net proceeds from the Note Offering to repay in full the Term Note, plus all accrued but unpaid interest, a make-whole interest payment and a prepayment premium on the Term Note. The 2021 not 2021 2021 2021 December 2020, 2021 2021 If the Company underwent a “fundamental change” (as defined in the Indenture), holders could have required that the Company repurchase for cash all or any portion of their 2021 2021 The Indenture included customary terms and covenants, including certain events of default after which the 2021 may As described in more detail below, in multiple exchanges occurring in December 2019 January 2020, 2021 2021 December 2019 In December 2019, December 2019 “December 2019 “December 2019 December 2019 “December 2019 2021 December 2019 December 2019 December 18, 2019, 2021 December 2019 December 2019 The December 2019 December 2019 2021 December 2019 December 2020, December 2019 December 2019 December 2019 December 2019 415 December 2019 $93.60 not x 2020 September 2019 December 2019 not December 2019 December 2019 December 2019 December 2019 4.985% December 2019 December 2019 December 2019 March 31, 2021, not December 2019 December 2019 December 2019 December 2019 December 2019 December 2019 The December 2019 December 2019 December 2019 December 2019 February 14, 2020 June 1, 2020, March 31, 2021, March 31, 2021 may The December 2019 December 2019 December 2019 $93.60 December 2019 The December 2019 December 2019 The December 2019 December 2019 may one In connection with entering into the December 2019 December 18, 2019, June 2, 2014, In connection with entering into the December 2019 “September 2019 September 2019 September 2019 December 2019 September 2019 September 2019 x 15 no September 2019 2 September 2019 may September 2019 September 2019 September December 2020, 15 In connection with entering into the September 2019 2 2 2 2 September 2019 $9.60 15 As of September 30, 2020, December 2019 The Company determined the changes to the Deerfield Convertible Note met the definition of a troubled debt restructuring under ASC 470 60, Troubled Debt Restructurings by Debtors no The changes to the 2021 December 2019 December 2019 December 2019 2021 January 2020 In January 2020, January 2020 “January 2020 January 2020 “January 2020 2021 January 2020 January 13, 2020, 2021 January 2020 The January 2020 December 2019 In connection with entering into the January 2020 December 2019 “December 2019 December 2019 December 2019 December 2019 December 2019 x 2020 December 2020, The changes to the 2021 January 2020 January 2020 January 2020 December 2020 Rights Agreement In December 2020, December 2020 “December 2020 December 2020 December 2019 January 2020 January 1, 2021, December 2020 2 Q4 December 2020 “December 2020 The December 2020 not March 31, 2023. Subject to the satisfaction or waiver of certain conditions specified in the December 2020 December 2020 June 2, 2014, March 31, 2023, ( July 1, 2021, The December 2020 February 19, 2015 ( December 2020 The Exchange Warrants issued pursuant to the December 2020 75% 2 1, no. 333 250945 4.985% In anticipation of the Public Offering, and to meet the Nasdaq Listing Requirements, the Company agreed in December 2020 December 2019 January 2020 December 31, 2020. Under the terms of the December 2020 January 12, 2021, ● Exchanged $31.5 million of the outstanding principal and accrued interest on the Facility Notes for (i) 31,476.98412 shares of Series B- 2 ● Made a payment of $30.3 million (the "Debt Payment"), in partial repayment of the remaining outstanding principal and accrued interest of the Facility Notes. Following the completion of these transactions, the aggregate balance of principal and accrued interest remaining outstanding under the Facility Notes was approximately $7.6 million. With respect to this remaining outstanding balance under the Facility Notes, the December 2020 ● The maturity date was changed to March 31, 2023, ● Interest would accrue at the rate of 6.75% per annum, payable quarterly, would be added to principal until June 30, 2021, The changes to the Facility Notes, under the December 2020 December 2020 December 2020 not nine September 30, 2021 The transactions contemplated under the December 2020 2 2 As a condition to closing of the December 2020 2 2 2 Each share of Series B- 2 $1,000 The Series B- 2 2 2 4.985% 2 not 2 $1,000 2 2 2 2 2 2 not 2 not not 2 2 2 2 Payoff of Facility Agreement Notes and Termination of Facility Agreement On February 8, 2021, Pursuant to the payoff letter, the Company paid a total of $8.0 million to the Facility Agreement Note Holders, representing the principal balance, accrued interest outstanding and a prepayment fee in repayment of the Company’s outstanding obligations under the Facility Agreement. Pursuant to the payoff letter, all outstanding indebtedness and obligations of the Company owing to the Facility Agreement Note Holders under the Facility Agreement have been paid in full. The Facility Agreement and the notes thereunder, as well as the security interests in the assets of the Company securing the Facility Agreement and note obligations, have been terminated. The Facility Agreement Note Holders will retain the warrants previously issued to them by the Company. The Company determined the payoff letter met the liability derecognition threshold under ASC 405 20, Liabilities - Extinguishment of Liabilities no nine September 30, 2021. PPP Loan On April 23, 2020, may June 2021, nine September 30, 2021.

Note D - Commitments and Contin

Note D - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	D. Commitments and Contingencies From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not not September 30, 2021 December 31, 2020

Note E - Preferred Stock and Wa

Note E - Preferred Stock and Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	E. Preferred Stock and Warrants Authorized, Issued, and Outstanding Preferred Stock As of September 30, 2021, As of December 31, 2020, December 31, 2020: Shares Authorized Shares Issued Shares Outstanding Series A convertible preferred stock, $0.0001 par value 9,578 9,577 — Series B-1 convertible preferred stock, $0.0001 par value 1,576 1,576 — Series B-2 convertible preferred stock, $0.0001 par value 27,000 — — In June 2021, 1 1 2 2 September 30, 2021, Series B- 2 Pursuant to the December 2020 January 12, 2021, 2 The Series B- 2 No 2 2 Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Series B- 2 Convertible Preferred Stock On January 11, 2021, December 2020 2 2 2 Immediately following, the closing of the Public Offering, pursuant to the terms of the December 2020 ● Exchanged approximately $31.5 million (the "Exchange") of the outstanding principal and accrued interest on the Facility Notes for (i) the Series B- 2 ● made a payment of approximately $30.3 million (the “Debt Payment”) in partial repayment of the remaining outstanding principal and accrued interest on the Facility Notes. Upon the closing of the Exchange and related Debt Payment, the amendments to the Facility Agreement, the Notes and the Investors’ Rights Agreement, dated as of February 19, 2015, December 2020 2 2 January 12, 2021. In March 2021, 2

Note F - Common Stock and Warra

Note F - Common Stock and Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	F. Common Stock and Warrants Authorized, Issued, and Outstanding Common Shares As of September 30, 2021 December 31, 2020 September 30, 2021 December 31, 2020 As of September 30, 2021 December 31, 2020 September 30, 2021 December 31, 2020 Conversion of Deerfield Convertible Note — 81,101 Conversion of January 2020 Note — 34,615 Conversion of December 2019 Notes — 625,747 Outstanding awards under equity incentive plans 1,169,379 355,785 Outstanding common stock warrants 4,252,600 151,442 Possible future issuances under equity incentive plans 4,314,435 47,825 Possible future issuances under employee stock purchase plans 1,500,000 — Total common shares reserved for future issuance 11,236,414 1,296,515 Common Stock Activity The following table summarizes common stock activity for the nine September 30, 2021 : Shares of Common Stock Balance as of December 31, 2020 4,537,321 Common stock issued as a result of the Public Offering 7,139,498 Common stock issued as a result of Series B-2 Preferred Stock conversions 4,842,699 Common stock issued as a result of warrant exercises 11,951,038 Common stock issued as compensation to third-parties 9,600 Balance as of March 31, 2021 28,480,156 Adjustment for cash paid in lieu of DTC fractional shares (1,356 ) Common stock issued as a result of warrant exercises 6,489,183 Common stock issued as compensation to third-parties 9,940 Balance as of June 30, 2021 34,977,923 Common stock issued as a result of warrant exercises 332,289 Common stock issued as compensation to third-parties 7,101 Balance as of September 30, 2021 35,317,313 Warrants On June 2, 2014, June 2, 2024, December 2020, January 2021 $93.60 June 2021 $46.25 February 2021 The Company determined that the Deerfield Warrant should be recorded as a liability and stated at fair value at each reporting period upon inception. As stated above, upon completion of the IPO, the Deerfield Warrant automatically converted into warrants to purchase the Company’s common stock. The Deerfield Warrant remains classified as a liability and is recorded at fair value at each reporting period since it can be settled in cash. Changes to the fair value of the warrant liability are recorded through the unaudited condensed statements of operations as a fair value adjustment (Note H). In connection with the APADAZ License Agreement, in October 2018, not four October 24, 2023. may December 2020, The Company determined that, since KVK qualifies as a customer under ASC 606, 815 815 606 September 30, 2021 December 31, 2020, Pre-Funded Warrants On January 12, 2021, January 2021, Warrants to Purchase Common Stock On January 12, 2021, December 2020 December 2020 fifth may may not 13 not 50% 50% not September 30, 2021, January 2021 Underwriter Warrant On January 12, 2021, February 3, 2021, September 30, 2021, January 2021 On January 26, 2021, “January 2021 “January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 The January 2021 fifth January 2021 January 2021 may may not January 2021 13 January 2021 January 2021 January 2021 not January 2021 January 2021 January 2021 January 2021 50% 50% January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 not January 2021 January 2021 January 2021 September 30, 2021, January 2021 January 2021 June 2021 In accordance with the January 2021 January 2021 January 2021 June 2021 On June 18, 2021, “June 2021 January 2021 "January 2021 “June 2021 January 2021 “June 2021 January 2021 January 2021 June 2021 June 2021 June 2021 January 2021 June 2021 June 2021 January 2021 June 2021 June 2021 $46.25 The June 2021 December 31, 2026, June 2021 June 2021 may may not June 2021 13 June 2021 June 2021 June 2021 not June 2021 June 2021 June 2021 June 2021 50% 50% June 2021 June 2021 June 2021 June 2021 June 2021 June 2021 not June 2021 June 2021 June 2021 September 30, 2021, June 2021 In accordance with the June 2021 June 2021 June 2021

Note G - Stock-based Compensati

Note G - Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	G. Stock-Based Compensation The Company maintains a stock-based compensation plan (the “Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO. In November 2014, April 2015, 2014 “2014 April 2015. 2014 June 2021, 2014 2014 January 1, 2031. may 2014 September 30, 2021. 2014 January 1 January 1, 2016, January 1, 2031, December 31 2014 January 1, 2021, 2014 During 2020, 2014 2020. three nine September 30, 2020, three nine September 30, 2021. During the three nine September 30, 2020, three nine September 30, 2021. Stock-based compensation expense recorded under the Incentive Stock Plan and the 2014 Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Research and development $ 201 $ 157 $ 630 $ 748 General and administrative 419 228 983 866 Severance expense — — — 420 Total stock-based compensation expense $ 620 $ 385 $ 1,613 $ 2,034 There was $0.3 million of stock-based compensation expense related to performance-based awards recognized during the nine September 30, 2020. nine September 30, 2021. three September 30, 2020, 2021.

Note H - Fair Value of Financia

Note H - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	H. Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three three ● Level 1—Observable ● Level 2—Observable ● Level 3—Unobservable no The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments. The fair values of the Deerfield Convertible Note, December 2019 January 2020 December 31, 2020. December 2019 January 2020 first 2021 September 30, 2021. December 2019 January 2020 3 December 2019 January 2020 December 31, 2020. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2021, December 31, 2020 ( Balance as of September 30, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 339 $ — $ — $ 339 Embedded Warrant Put Option 22 — — 22 KVK Warrant liability 35 — 35 — Total liabilities $ 396 $ — $ 35 $ 361 Balance as of December 31, 2020 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 230 $ — $ — $ 230 Embedded Warrant Put Option 25 — — 25 Deerfield Note Conversion Feature — — — — KVK Warrant liability 49 — 49 — Total liabilities $ 304 $ — $ 49 $ 255 The Company’s Deerfield Warrant liability and embedded Warrant Put Option are, and the embedded Deerfield Note Put Option was, measured at fair value on a recurring basis. As of September 30, 2021, December 31, 2020, December 31, 2020), three nine September 30, 2021, 2020 The derivative liability for the Deerfield Warrant was $339,000 and $230,000 at September 30, 2021, December 31, 2020, September 30, 2021 December 31, 2020, no December 31, 2020. 10% first 2023. The Company’s KVK Warrant liability is measured at fair value on a recurring basis. As of September 30, 2021, December 31, 2020, no not not three nine September 30, 2021, 2020 A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Balance as of beginning of period $ 666 $ 38 $ 255 $ 96 Adjustment to fair value (305 ) 115 106 57 Balance as of end of period $ 361 $ 153 $ 361 $ 153

Note I - Net Loss Per Share

Note I - Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	I. Net Loss Per Share Under the two No no two two Diluted net loss per share of common stock is the same as basic net loss per share of common stock for the three nine September 30, 2020, Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Conversion of Deerfield Convertible Note — 79,748 — 79,748 Conversion of January 2020 Note — 34,037 — 34,037 Conversion of December 2019 Notes — 615,307 — 615,307 Awards under equity incentive plans 1,169,379 354,379 1,169,379 354,379 Common stock warrants 4,101,158 151,442 4,221,350 151,442 Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 5,270,537 1,234,913 5,390,729 1,234,913 A reconciliation from net loss to basic net loss per share of common stock, basic net loss attributable to common stockholders per share of common stock and diluted net loss attributable to common stockholders per share of common stock for the three nine September 30, 2021, 2020 Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Basic net loss per share of common stock: Net loss $ (1,759 ) $ (3,009 ) $ (5,852 ) $ (7,904 ) Less: Net loss attributable to participating securities — — — — Undistributed net loss, basic $ (1,759 ) $ (3,009 ) $ (5,852 ) $ (7,904 ) Weighted average number of shares of common stock outstanding, basic 35,218 4,425 27,905 3,795 Basic net loss per share of common stock $ (0.05 ) $ (0.68 ) $ (0.21 ) $ (2.08 ) Net loss $ (1,759 ) $ (3,009 ) $ (5,852 ) $ (7,904 ) Less: Dividends declared or accumulated — — (54,342 ) — Net loss attributable to common stockholders $ (1,759 ) $ (3,009 ) $ (60,194 ) $ (7,904 ) Less: Net loss attributable to participating securities — — — — Undistributed net loss attributable to shares of common stockholders, basic $ (1,759 ) $ (3,009 ) $ (60,194 ) $ (7,904 ) Weighted average number of shares of common stock outstanding, basic 35,218 4,425 27,905 3,795 Basic net loss attributable to common stockholders per share of common stock $ (0.05 ) $ (0.68 ) $ (2.16 ) $ (2.08 ) Diluted net loss per share of common stock: Undistributed net loss attributable to common stockholders $ (1,759 ) $ (3,009 ) $ (60,194 ) $ (7,904 ) Less: Fair value adjustment income related to Deerfield Warrant liability (290 ) — — — Less: Fair value adjustment income related to embedded Warrant Put Option (16 ) — — — Less: Fair value adjustment income related to KVK Warrant liability (27 ) — (14 ) — Undistributed net loss attributable to common stockholders, diluted $ (2,092 ) $ (3,009 ) $ (60,208 ) $ (7,904 ) Weighted average number of shares of common stock outstanding, basic 35,218 4,425 27,905 3,795 Dilutive effect of awards under equity incentive plans — — — — Dilutive effect of Deerfield Warrant 0 — — — Dilutive effect of KVK Warrant 0 — 0 — Dilutive effect of other common stock warrants — — — — Weighted average number of shares of common stock outstanding, diluted 35,218 4,425 27,905 3,795 Diluted net loss attributable to common stockholders per share of common stock $ (0.06 ) $ (0.68 ) $ (2.16 ) $ (2.08 )

Note J - Severance Expense

Note J - Severance Expense	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	J. Severance Expense In February 2020, June 2015. nine September 30, 2020. December 31, 2020, three September 30, 2020, three nine September 30, 2021, September 30, 2021,

Note K - Leases

Note K - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lease Disclosure [Text Block]	K. Leases The Company has operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. The Company's leases have remaining lease terms of less than 1 year to approximately 4 years, some of which include options to extend the leases for up to 5 years, and some which include options to terminate the leases within 1 year. In February 2020, one two February 2026. October 2020, 19. Effective June 1, 2021, one two February 2026. The components of lease expense were as follows (in thousands): Three months ended September 30, Nine months ended September 30, Lease Cost 2021 2020 2021 2020 Finance lease cost: Amortization of right-of-use assets $ 32 $ 31 $ 96 $ 92 Interest on lease liabilities 2 4 9 19 Total finance lease cost 34 35 105 111 Operating lease cost 91 91 274 272 Short-term lease cost 50 49 149 160 Variable lease cost 13 14 34 41 Less: sublease income (39 ) (40 ) (52 ) (93 ) Total lease costs $ 149 $ 149 $ 510 $ 491 Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended September 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 9 $ 19 Financing cash flows from finance leases 156 168 Operating cash flows from operating leases 344 334 Operating cash flows from short-term leases 149 160 Operating cash flows from variable lease costs 34 41 Right-of-use assets obtained in exchange for lease liabilities: Finance leases $ — $ — Operating leases — 20 Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate): September 30, December 31, 2021 2020 Finance Leases Property and equipment, at cost $ 1,031 $ 1,031 less: accumulated depreciation and amortization (619 ) (523 ) Property and equipment, net $ 412 $ 508 Other current liabilities $ 32 $ 172 Other long-term liabilities 7 22 Total finance lease liabilities $ 39 $ 194 Operating Leases Operating lease right-of-use assets $ 1,186 $ 1,350 Total operating lease right-of-use assets $ 1,186 $ 1,350 Current portion of operating lease liabilities $ 349 $ 327 Operating lease liabilities, less current portion 1,324 1,587 Total operating lease liabilities $ 1,673 $ 1,914 Weighted Average Remaining Lease Term Finance leases (years) 1 1 Operating leases (years) 4 5 Weighted Average Discount Rate Finance leases 10.5 % 8.5 % Operating leases 7.5 % 7.5 % Maturities of lease liabilities were as follows (in thousands): Finance Operating Year Ending December 31, Leases Leases 2021 (excluding the nine months ended September 30, 2021) $ 18 $ 116 2022 18 463 2023 6 472 2024 — 484 2025 — 390 Thereafter — 30 Total lease payments 42 1,955 Less: future interest expense (3 ) (282 ) Lease liabilities $ 39 $ 1,673

Note L - Subsequent Events

Note L - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	L. Subsequent Events On October 19, 2021, October 19, 2021, January 2021.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company commenced recognizing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers 606” January 1, 2018. Arrangements with Multiple-Performance Obligations From time to time, the Company enters into arrangements for research and development, manufacturing and/or commercialization services. Such arrangements may In arrangements involving more than one not The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not Licensing Agreements The Company enters into licensing agreements with licensees that fall under the scope of ASC 606. The terms of the Company’s licensing agreements typically include one may As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may Up-front Fees: Milestone Payments: not not not may KP415 In September 2019, “KP415 KP415 KP484, KP879, KP922 KP484, KP415 KP484; KP415 KP415 KP415 Commave also agreed to be responsible for and reimburse the Company for all of the development, commercialization and regulatory expenses incurred on the licensed products, subject to certain limitations as set forth in the KP415 The KP415 KP484. KP484; In accordance with the terms of the Company’s March 20, 2012 KP484, KP879 KP1077 KP415 The KP415 606, not KP415 606, third two $10.0 KP415 The consideration allocated to the grant of the exclusive, worldwide license was $10.0 KP415 KP415 The consideration allocated to the performance of consulting services, which includes the reimbursement of out-of-pocket third KP415 third third no third third third third 606 third third KP415 September 30, 2021, third Under the KP415 first 1 may may KP415 KP415 first not third 606 not not The Company is entitled to additional payments from Commave conditioned upon the achievement of specified regulatory milestones related to AZSTARYS and KP484 KP415 KP415 not not not For example, in May 2020, KP415 two second 2020 second 2020. In April 2021, No. 1 KP415 "KP415 KP415 KP415 KP415 KP415 March 2, 2021. May 7, 2021. KP415 KP415 Pursuant to the KP415 KP922, no Per the KP415 March 2021, May 2021. two first 2021 first second 2021, 340 40, Contracts with Customers first second 2021, For the three September 30, 2021, KP415 three September 30, 2020, KP415 nine September 30, 2021 2020, KP415 September 30, 2021 December 31, 2020. APADAZ License Agreement In October 2018, Pursuant to the APADAZ License Agreement, KVK agreed to pay the Company certain payments and cost reimbursements of an estimated $3.4 million, which includes a payment of $2.0 million within 10 four The APADAZ License Agreement will terminate on the later of the date that all of the patent rights for APADAZ have expired in the United States or KVK’s cessation of commercialization of APADAZ in the United States. KVK may 90 may 18 may six may 30 not The APADAZ License Agreement also established a joint steering committee, which monitors progress of the commercialization of APADAZ. Consulting Arrangements The Company enters into consulting arrangements with third 606. may third Corium Consulting Agreement In July 2020, KP415 Under the Corium Consulting Agreement, the Company is entitled to receive payments from Corium of up to $15.6 million, $13.6 million of which will be paid in quarterly installments through March 31, 2022. The Corium Consulting Agreement is within the scope of ASC 606, not 606, third third not not not The Company determined that the performance of consulting services, including reimbursement of third third 606 September 30, 2021, third For the three nine September 30, 2021, three nine September 30, 2020, September 30, 2021, December 31, 2020, Other Consulting Arrangements For the three September 30, 2021 2020, nine September 30, 2021 2020, September 30, 2021 December 31, 2020.
Receivable [Policy Text Block]	Accounts and Other Receivables Accounts and other receivables consist of receivables under the KP415 KP415 third September 30, 2021, December 31, 2020, September 30, 2021, December 31, 2020, no
New Accounting Pronouncements, Policy [Policy Text Block]	Application of New or Revised Accounting Standards—Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 Measurement of Credit Losses on Financial Instruments 2016 13” not not December 15, 2019, 2016 13 not In August 2018, 2018 13, Fair Value Measurement (Topic 820 Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement 2018 13” 820, Conceptual Framework for Financial Reporting Chapter 8: August 28, 2018, December 15, 2019, 3 2018 13 not Application of New or Revised Accounting Standards—Not Yet Adopted In August 2020, 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815 40 Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06” December 15, 2021, not 2020 06 In May 2021, 2021 04, Earnings Per Share (Topic 260 470 50 718 815 40 2021 04” December 15, 2021, not 2021 04

Note E - Preferred Stock and _2

Note E - Preferred Stock and Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Shares Authorized Shares Issued Shares Outstanding Series A convertible preferred stock, $0.0001 par value 9,578 9,577 — Series B-1 convertible preferred stock, $0.0001 par value 1,576 1,576 — Series B-2 convertible preferred stock, $0.0001 par value 27,000 — —

Note F - Common Stock and War_2

Note F - Common Stock and Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]	September 30, 2021 December 31, 2020 Conversion of Deerfield Convertible Note — 81,101 Conversion of January 2020 Note — 34,615 Conversion of December 2019 Notes — 625,747 Outstanding awards under equity incentive plans 1,169,379 355,785 Outstanding common stock warrants 4,252,600 151,442 Possible future issuances under equity incentive plans 4,314,435 47,825 Possible future issuances under employee stock purchase plans 1,500,000 — Total common shares reserved for future issuance 11,236,414 1,296,515
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Shares of Common Stock Balance as of December 31, 2020 4,537,321 Common stock issued as a result of the Public Offering 7,139,498 Common stock issued as a result of Series B-2 Preferred Stock conversions 4,842,699 Common stock issued as a result of warrant exercises 11,951,038 Common stock issued as compensation to third-parties 9,600 Balance as of March 31, 2021 28,480,156 Adjustment for cash paid in lieu of DTC fractional shares (1,356 ) Common stock issued as a result of warrant exercises 6,489,183 Common stock issued as compensation to third-parties 9,940 Balance as of June 30, 2021 34,977,923 Common stock issued as a result of warrant exercises 332,289 Common stock issued as compensation to third-parties 7,101 Balance as of September 30, 2021 35,317,313

Note G - Stock-based Compensa_2

Note G - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Research and development $ 201 $ 157 $ 630 $ 748 General and administrative 419 228 983 866 Severance expense — — — 420 Total stock-based compensation expense $ 620 $ 385 $ 1,613 $ 2,034

Note H - Fair Value of Financ_2

Note H - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Balance as of September 30, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 339 $ — $ — $ 339 Embedded Warrant Put Option 22 — — 22 KVK Warrant liability 35 — 35 — Total liabilities $ 396 $ — $ 35 $ 361 Balance as of December 31, 2020 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 230 $ — $ — $ 230 Embedded Warrant Put Option 25 — — 25 Deerfield Note Conversion Feature — — — — KVK Warrant liability 49 — 49 — Total liabilities $ 304 $ — $ 49 $ 255
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Balance as of beginning of period $ 666 $ 38 $ 255 $ 96 Adjustment to fair value (305 ) 115 106 57 Balance as of end of period $ 361 $ 153 $ 361 $ 153

Note I - Net Loss Per Share (Ta

Note I - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Conversion of Deerfield Convertible Note — 79,748 — 79,748 Conversion of January 2020 Note — 34,037 — 34,037 Conversion of December 2019 Notes — 615,307 — 615,307 Awards under equity incentive plans 1,169,379 354,379 1,169,379 354,379 Common stock warrants 4,101,158 151,442 4,221,350 151,442 Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 5,270,537 1,234,913 5,390,729 1,234,913
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Basic net loss per share of common stock: Net loss $ (1,759 ) $ (3,009 ) $ (5,852 ) $ (7,904 ) Less: Net loss attributable to participating securities — — — — Undistributed net loss, basic $ (1,759 ) $ (3,009 ) $ (5,852 ) $ (7,904 ) Weighted average number of shares of common stock outstanding, basic 35,218 4,425 27,905 3,795 Basic net loss per share of common stock $ (0.05 ) $ (0.68 ) $ (0.21 ) $ (2.08 ) Net loss $ (1,759 ) $ (3,009 ) $ (5,852 ) $ (7,904 ) Less: Dividends declared or accumulated — — (54,342 ) — Net loss attributable to common stockholders $ (1,759 ) $ (3,009 ) $ (60,194 ) $ (7,904 ) Less: Net loss attributable to participating securities — — — — Undistributed net loss attributable to shares of common stockholders, basic $ (1,759 ) $ (3,009 ) $ (60,194 ) $ (7,904 ) Weighted average number of shares of common stock outstanding, basic 35,218 4,425 27,905 3,795 Basic net loss attributable to common stockholders per share of common stock $ (0.05 ) $ (0.68 ) $ (2.16 ) $ (2.08 ) Diluted net loss per share of common stock: Undistributed net loss attributable to common stockholders $ (1,759 ) $ (3,009 ) $ (60,194 ) $ (7,904 ) Less: Fair value adjustment income related to Deerfield Warrant liability (290 ) — — — Less: Fair value adjustment income related to embedded Warrant Put Option (16 ) — — — Less: Fair value adjustment income related to KVK Warrant liability (27 ) — (14 ) — Undistributed net loss attributable to common stockholders, diluted $ (2,092 ) $ (3,009 ) $ (60,208 ) $ (7,904 ) Weighted average number of shares of common stock outstanding, basic 35,218 4,425 27,905 3,795 Dilutive effect of awards under equity incentive plans — — — — Dilutive effect of Deerfield Warrant 0 — — — Dilutive effect of KVK Warrant 0 — 0 — Dilutive effect of other common stock warrants — — — — Weighted average number of shares of common stock outstanding, diluted 35,218 4,425 27,905 3,795 Diluted net loss attributable to common stockholders per share of common stock $ (0.06 ) $ (0.68 ) $ (2.16 ) $ (2.08 )

Note K - Leases (Tables)

Note K - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three months ended September 30, Nine months ended September 30, Lease Cost 2021 2020 2021 2020 Finance lease cost: Amortization of right-of-use assets $ 32 $ 31 $ 96 $ 92 Interest on lease liabilities 2 4 9 19 Total finance lease cost 34 35 105 111 Operating lease cost 91 91 274 272 Short-term lease cost 50 49 149 160 Variable lease cost 13 14 34 41 Less: sublease income (39 ) (40 ) (52 ) (93 ) Total lease costs $ 149 $ 149 $ 510 $ 491
Schedule of Leases Cash Flow Information [Table Text Block]	Nine months ended September 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 9 $ 19 Financing cash flows from finance leases 156 168 Operating cash flows from operating leases 344 334 Operating cash flows from short-term leases 149 160 Operating cash flows from variable lease costs 34 41 Right-of-use assets obtained in exchange for lease liabilities: Finance leases $ — $ — Operating leases — 20
Schedule of Leases Balance Sheet Information [Table Text Block]	September 30, December 31, 2021 2020 Finance Leases Property and equipment, at cost $ 1,031 $ 1,031 less: accumulated depreciation and amortization (619 ) (523 ) Property and equipment, net $ 412 $ 508 Other current liabilities $ 32 $ 172 Other long-term liabilities 7 22 Total finance lease liabilities $ 39 $ 194 Operating Leases Operating lease right-of-use assets $ 1,186 $ 1,350 Total operating lease right-of-use assets $ 1,186 $ 1,350 Current portion of operating lease liabilities $ 349 $ 327 Operating lease liabilities, less current portion 1,324 1,587 Total operating lease liabilities $ 1,673 $ 1,914 Weighted Average Remaining Lease Term Finance leases (years) 1 1 Operating leases (years) 4 5 Weighted Average Discount Rate Finance leases 10.5 % 8.5 % Operating leases 7.5 % 7.5 %
Operating and Finance Lease, Liability, Maturity [Table Text Block]	Finance Operating Year Ending December 31, Leases Leases 2021 (excluding the nine months ended September 30, 2021) $ 18 $ 116 2022 18 463 2023 6 472 2024 — 484 2025 — 390 Thereafter — 30 Total lease payments 42 1,955 Less: future interest expense (3 ) (282 ) Lease liabilities $ 39 $ 1,673

Note A - Description of Busin_2

Note A - Description of Business and Basis of Presentation (Details Textual) $ / shares in Units, $ in Millions	Sep. 30, 2021$ / sharesshares	Jul. 12, 2021USD ($)	Feb. 01, 2021shares	Jan. 12, 2021USD ($)$ / sharesshares	Jan. 08, 2021$ / sharesshares	Dec. 23, 2020$ / shares	Feb. 29, 2020USD ($)shares	May 31, 2020USD ($)shares	Jul. 02, 2021USD ($)	Feb. 03, 2021shares	Dec. 31, 2020$ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001					$ 0.0001					$ 0.0001
Sale of Stock, Authorized Amount | $		$ 350
Lincoln Park [Member]
Sale of Securities, Value, Available to Issue | $							$ 4
Purchase Agreement, Term (Month)							12 months
Purchase Agreement, Additional Shares to Be Issued as Commitment Shares (in shares)							19,289
Purchase Agreement, Maximum Shares to be Issued (in shares)							579,260
Stock Issued During Period, Shares, New Issues (in shares)								559,971
Proceeds from Issuance of Common Stock | $								$ 2.3
Roth Capital Partners, LLC [Member] | Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				926,844	926,844
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.0001
Roth Capital Partners, LLC [Member] | Public Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				12,078,361	7,692,307
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 6.50	$ 6.50
Class of Warrant or Right, Offering Price, Per Related Warrant (in dollars per share) | $ / shares					$ 0.0001
Roth Capital Partners, LLC [Member] | Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				806,932	754,035					18,702
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 8.125
Over Allotment Options, Number of Shares for Warrants (in shares)					1,153,846
Roth Capital Partners, LLC [Member] | Underwriting Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					6,765,463
Shares and Warrants Issued, Price Per Share (in dollars per share) | $ / shares					$ 6.50
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 6.4999
Proceeds from Issuance or Sale of Equity, Total | $				$ 52.4
Roth Capital Partners, LLC [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)			374,035
Purchase Agreement Optional Period to Shares (Day)					45 days
Purchase Agreement, Maximum, Additional Shares Available for Purchase During the Optional Period (in shares)					1,153,846
JMP and RBCCM [Member] | ATM Agreement Sales [Member]
Stock Issued During Period, Shares, New Issues (in shares)	0
Equity Distribution Agreement, Maximum Aggregate Offering Price | $									$ 75
Equity Distribution Agreement, Commission Fee, Percentage of Gross Sales									3.00%
Stock Issued During Period, Value, New Issues | $		$ 75
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						16

Note B - Summary of Significa_2

Note B - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Apr. 08, 2021	Sep. 03, 2019	Mar. 20, 2012	Oct. 31, 2018	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	May 31, 2021	Mar. 02, 2021	Dec. 31, 2020	Jul. 31, 2020	May 31, 2020
Revenue from Contract with Customer, Including Assessed Tax					$ 1,965			$ 1,925			$ 26,068	$ 10,922
Accounts Receivable, Allowance for Credit Loss, Ending Balance					0						0				$ 0
Consulting Services [Member]
Revenue from Contract with Customer, Including Assessed Tax					0			0			200	1,700
Deferred Revenue, Total					0						0				0
GPC Member | License [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 10,000	$ 10,000			0						20,000	7,300
Revenue Recognition, Milestone Method, Revenue to be Recognized	10,000	63,000											$ 10,000
Revenue Recognition, Milestone Method, Additional Revenue to be Recognized	$ 590,000	$ 420,000
Regulatory Milestone Revenue to Be Earned Following FDA Acceptance														$ 10,000			$ 5,000
Contract with Customer, Liability, Revenue Recognized						$ 10,000	$ 10,000		$ 5,000
Deferred Revenue, Total					0						0				0
Aquestive Therapeutics [Member] | License [Member]
Royalty Revenue, Percent			10.00%
Royalty Expense										$ 1,000
KVK [Member] | License [Member]
License Agreement, Estimated Pre-launch Payments and Reimbursements				$ 3,400
License Agreement, Pre-launch Payment Reimbursement Within 10 Days of Initial Adoption Milestone				2,000
License Agreement, Additional Payments Upon Achievement of Sales Milestone				$ 53,000
KVK [Member] | License [Member] | Minimum [Member]
License Agreement, Percentage of Net Profits				30.00%
KVK [Member] | License [Member] | Maximum [Member]
License Agreement, Percentage of Net Profits				50.00%
Corium, Inc [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total					1,200						1,200				2,100
Corium, Inc [Member] | Consulting Services [Member]
Revenue from Contract with Customer, Including Assessed Tax					2,000			$ 1,900			5,900	$ 1,900
Deferred Revenue, Total					$ 300						$ 300				100
Consulting Agreement, Maximum Amount to be Received																$ 15,600
Contract with Customer, Asset, after Allowance for Credit Loss, Total																13,600
Consulting Agreement, Conditional Milestone Achievement to be Received																$ 2,000
Percentage of Consulting Services and Out-of-pocket Third-party Research and Development Costs Recognized					70.00%						70.00%
Accounts Receivable, after Allowance for Credit Loss, Current, Total					$ 100						$ 100				$ 400

Note C - Debt Obligations (Deta

Note C - Debt Obligations (Details Textual) - USD ($)	Feb. 08, 2021	Jan. 12, 2021	Jan. 01, 2021	Apr. 23, 2020	Jan. 13, 2020	Dec. 18, 2019	Feb. 09, 2016	Jun. 02, 2014	Jun. 30, 2018	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Sep. 30, 2021	Jun. 18, 2021	Mar. 31, 2021	Jan. 26, 2021	Dec. 31, 2019	Sep. 30, 2019	Sep. 02, 2019	Jun. 30, 2016
Convertible Notes Payable, Total										$ 0		$ 68,200,000	$ 0
Interest Paid, Excluding Capitalized Interest, Operating Activities										213,000	$ 71,000
Debt Instrument, Convertible, Minimum Conversion Price (in dollars per share)																	$ 9.328
Proceeds from Issuance of Long-term Debt, Total										$ 0	$ 781,000
Conversion from Deerfield Convertible Note to Common Stock [Member]
Debt Conversion, Original Debt, Amount									$ 3,333,333
Debt Conversion, Accrued Interest									$ 168,288
Debt Conversion, Converted Instrument, Shares Issued (in shares)									37,410
Conversion of December 2019 Notes into Common Stock [Member]
Debt Conversion, Original Debt, Amount													$ 17,100,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)													1,777,437
December 2020 Exchange Agreement [Member]
Debt Conversion, Original Debt, Amount		$ 31,500,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)		31,476.98412
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		3,632,019
Deerfield Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)																	93.60
2021 Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)							$ 17.11					$ 273.76
Debt Conversion, Original Debt, Amount							$ 1,000					$ 1,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)							58.4454					3.6528
Debt Instrument, Interest Rate, Stated Percentage							5.50%
Debt Instrument, Face Amount							$ 86,300,000
Proceeds from Debt, Net of Issuance Costs							82,800,000
Repayments of Long-term Debt, Total							18,600,000
Debt Instrument, Sinking Fund Payment							$ 0
Debt Instrument Repurchase Price Equal to Percentage of Principal Amount							100.00%
Debt Instrument, Cancellation of Debt, Amount					$ 3,037,354	$ 71,418,011
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 37,354	$ 745,011
Debt Instrument, Percentage of Accrued Interest Paid						50.00%
The 2019 Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 5.85	$ 17.11						$ 93.60					273.76
Debt Instrument, Interest Rate, Stated Percentage						6.75%
Debt Instrument, Face Amount						$ 71,418,011
Debt Instrument, Percentage of Accrued Interest Paid					50.00%
Debt Instrument, Convertible, Minimum Conversion Price (in dollars per share)					$ 0.583												$ 0.38
Debt Instrument, Convertible, Conversion Restriction Percentage of Common Stock						4.985%
Beneficial Ownership, Cap Limit, Percentage						19.985%
Debt Instrument, Convertible, Floor Price (in dollars per share)												$ 9.328
January 2020 Note [Member]
Debt Instrument, Face Amount					$ 3,037,354
The December 2020 Exchange Agreement [Member]
Repayments of Debt			$ 30,300,000
The December 2019 and January 2020 Notes [Member]
Long-term Debt, Gross												$ 60,800,000
Deerfield Facility Agreement [Member]
Long-term Debt, Gross												7,500,000
The Facility Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		6.75%
Repayments of Long-term Debt, Total		$ 30,300,000
Long-term Debt, Total		$ 7,600,000										$ 69,400,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total				$ 800,000
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 60,000,000
Line of Credit Facility, Interest Rate at Period End								9.75%												6.75%
Debt Instrument, Interest Rate, Stated Percentage																		6.75%	9.75%
Convertible Notes Payable, Current															$ 6,980,824
Debt Covenant, Debt Financing Restriction								$ 750,000
Repayments of Long-term Debt, Total	$ 8,000,000
Debt Instrument, Convertible, Minimum Conversion Price (in dollars per share)						$ 0.60
Conversion of Stock, Maximum Shares Issued (in shares)						28,439,015
Debt Instrument, Convertible, Optional Conversion Feature, Exchange Price (in dollars per share)												$ 9.60
Debt Instrument, Convertible Optional Conversion Feature Shares Issuable Upon Exchange (in shares)												1,777,437
Deerfield Facility Agreement [Member] | Deerfield Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 0.78
Deerfield Facility Agreement [Member] | Deerfield Warrant [Member] | IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,923,077
Deerfield Facility Agreement [Member] | Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								14,423,076
Deerfield Facility Agreement [Member] | Term Notes [Member]
Proceeds from Secured Notes Payable								$ 15,000,000
Deerfield Facility Agreement [Member] | Deerfield Convertible Notes [Member]
Proceeds from Secured Notes Payable								$ 10,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 5.85				$ 93.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												120,192
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 5.85				$ 93.60		$ 38.34		$ 46.25

Note D - Commitments and Cont_2

Note D - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Loss Contingency Accrual, Ending Balance	$ 0	$ 0

Note E - Preferred Stock and _3

Note E - Preferred Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Jan. 12, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Preferred Stock, Shares Authorized (in shares)					10,000,000	10,000,000
Preferred Stock, Shares Issued, Total (in shares)					0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0
Conversion of Series B-2 Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)			4,842,699	4,842,699
The Facility Notes [Member]
Repayments of Long-term Debt, Total	$ 30.3
December 2020 Exchange Agreement [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,476.98412
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)	3,632,019
Debt Conversion, Original Debt, Amount	$ 31.5
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)		9,578		9,578		9,578
Preferred Stock, Shares Issued, Total (in shares)						1,576
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						1,576
Series B-1 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)						27,000
Preferred Stock, Shares Issued, Total (in shares)		1,576		1,576
Series B-2 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized, Elimated (in shares)		31,480
Preferred Stock, Convertible, Shares Issuable (in shares)	4,842,690
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 6.4999

Note E - Preferred Stock and _4

Note E - Preferred Stock and Warrants - Preferred Stock Issued and Outstanding (Details) - shares	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Preferred Stock, Shares Authorized (in shares)	10,000,000		10,000,000
Preferred Stock, Shares Issued, Total (in shares)	0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)		9,578	9,578
Preferred Stock, Shares Issued, Total (in shares)			1,576
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			1,576
Series B-1 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)			27,000
Preferred Stock, Shares Issued, Total (in shares)		1,576

Note F - Common Stock and War_3

Note F - Common Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2021	Jan. 26, 2021	Jan. 12, 2021	Oct. 25, 2018	Jun. 02, 2014	Jan. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 18, 2021	Sep. 30, 2021	Sep. 30, 2020	Feb. 03, 2021	Jan. 08, 2021	Dec. 31, 2020
Common Stock, Shares Authorized (in shares)	250,000,000						250,000,000					250,000,000				250,000,000
Common Stock, Shares, Issued, Total (in shares)	35,317,313						35,317,313					35,317,313				4,537,321
Stock Issued During Period, Shares, Warrant Exercises (in shares)							332,289	6,489,183	11,951,038
Proceeds from Warrant Exercises												$ 30,819	$ 0
Preferred Stock Dividends and Other Adjustments, Total							$ 0			$ 0		$ 54,342	$ 0
Common Stock, Shares, Outstanding, Ending Balance (in shares)	35,317,313						35,317,313	34,977,923	28,480,156			35,317,313				4,537,321
Other Noncurrent Assets [Member]
Contract with Customer, Asset, after Allowance for Credit Loss, Total	$ 400						$ 400					$ 400				$ 400
Deerfield Warrant [Member]
Class of Warrant or Right Issued (in shares)					14,423,076
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 46.25									$ 38.34					$ 93.60
Deerfield Warrant [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,923,077											120,192
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 46.25			$ 5.85						$ 38.34					$ 93.60
Warrant Issued to KVK [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				500,000												31,250
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2.30												$ 36.80
Class of Warrant or Right, Additional Shares Exercisable for Each Milestones (in shares)				125,000
Pre-funded Warrants [Member] | Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			926,844												926,844
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.0001
Stock Issued During Period, Shares, Warrant Exercises (in shares)						926,841
Proceeds from Warrant Exercises						$ 72,000
Public Offering Warrants [Member] | Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			12,078,361												7,692,307
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 6.50												$ 6.50
Stock Issued During Period, Shares, Warrant Exercises (in shares)												3,030,881
Proceeds from Warrant Exercises												$ 16,900
Warrants and Rights Outstanding, Term (Year)			5 years
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise			4.99%
Class of Warrants or Right, Exercised During Period (in shares)												3,461,858
Underwriter Warrants [Member] | Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			806,932											18,702	754,035
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 8.125
Stock Issued During Period, Shares, Warrant Exercises (in shares)												400,000
Proceeds from Warrant Exercises												$ 3,300
Class of Warrants or Right, Exercised During Period (in shares)												400,000
Over Allotment Options, Percentage of Common Stock Outstanding for Warrants			5.00%
Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		6,620,358
Proceeds from Warrant Exercises		$ 44,000
Placement Agent Fee, Percentage		6.00%
January 2021 Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		7,944,430									6,117,509
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.36
Stock Issued During Period, Shares, Warrant Exercises (in shares)												1,676,921
Proceeds from Warrant Exercises	$ 10,700										$ 39,100
Warrants and Rights Outstanding, Term (Year)		5 years
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise		4.99%
Class of Warrants or Right, Exercised During Period (in shares)												1,676,921
Warrants Issued Upon Exchange, Percentage of Shares Issued Upon Exercise		120.00%
Class of Warrant, Purchase Price Per Warrant (in dollars per share)		$ 0.125
Placement Agent Fee, Percentage											6.00%
Maximum Percent of Common Stock Ownership Allowed Per Holder After Warrant Exercise Upon Holders Selection		9.99%
Preferred Stock Dividends and Other Adjustments, Total												$ 37,400
June 2021 Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											1,529,379
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 16.50
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise											4.99%
Class of Warrants or Right, Exercised During Period (in shares)												0
Warrants Issued Upon Exchange, Percentage of Shares Issued Upon Exercise											25.00%
Class of Warrant, Purchase Price Per Warrant (in dollars per share)											$ 0.125
Maximum Percent of Common Stock Ownership Allowed Per Holder After Warrant Exercise Upon Holders Selection											9.99%
Preferred Stock Dividends and Other Adjustments, Total												$ 16,900

Note F - Common Stock and War_4

Note F - Common Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Sep. 30, 2021	Dec. 31, 2020
Common shares reserved for future issuance (in shares)	11,236,414	1,296,515
Warrant [Member]
Common shares reserved for future issuance (in shares)	4,252,600	151,442
Share-based Payment Arrangement [Member]
Common shares reserved for future issuance (in shares)	1,169,379	355,785
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	4,314,435	47,825
Possible Future Issuances Under Employee Stock Purchase Plans [Member]
Common shares reserved for future issuance (in shares)	1,500,000	0
January 2020 Note [Member]
Common shares reserved for future issuance (in shares)	0	34,615
2021 Notes [Member]
Common shares reserved for future issuance (in shares)	0	625,747
Convertible Notes Payable [Member]
Common shares reserved for future issuance (in shares)	0	81,101

Note F - Common Stock and War_5

Note F - Common Stock and Warrants - Common Stock Activity (Details) - shares	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021
Balance (in shares)	34,977,923	28,480,156	4,537,321	4,537,321	4,537,321
Common stock issued as a result of warrant exercises (in shares)	332,289	6,489,183	11,951,038
Common stock issued as compensation to third-parties (in shares)	7,101	9,940	9,600
Adjustment for cash paid in lieu of DTC fractional shares (in shares)		(1,356)
Balance (in shares)	35,317,313	34,977,923	28,480,156	34,977,923	35,317,313
Conversion of Series B-2 Preferred Stock into Common Stock [Member]
Common stock issued as a result of Series B-2 Preferred Stock conversions (in shares)			4,842,699	4,842,699
Underwritten Public Offering [Member]
Common stock issued as a result of the Public Offering (in shares)			7,139,498

Note G - Stock-based Compensa_3

Note G - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expense			$ 620	$ 385		$ 1,613	$ 2,034
Performance Shares [Member]
Share-based Payment Arrangement, Expense			$ 0	$ 0		$ 400	$ 300
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		4,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			5,489,660			5,489,660
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding					4.00%
Increase in Common Stock Reserved for Issuance (in shares)	181,492
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)			0	1,384		0	9,205
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			0	279		0	279

Note G - Stock-based Compensa_4

Note G - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock based compensation expense	$ 620	$ 385	$ 1,613	$ 2,034
Research and Development Expense [Member]
Stock based compensation expense	201	157	630	748
General and Administrative Expense [Member]
Stock based compensation expense	419	228	983	866
Severance Expense [Member]
Stock based compensation expense	$ 0	$ 0	$ 0	$ 420

Note H - Fair Value of Financ_3

Note H - Fair Value of Financial Instruments (Details Textual)	9 Months Ended
	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Deerfield Warrant Liability [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 339,000	$ 230,000
Liabilities, Fair Value Disclosure, Increase from Ten Percent Increase in Enterprise Value	58,000
Liabilities, Fair Value Disclosure, Estimated Amount of Weighted-average Probability of Liquidity Event	63,300,000
Liabilities, Fair Value Disclosure, Estimated Amount of Weighted-average Probability of Fundamental Change	$ 800,000,000
Deerfield Warrant Liability [Member] | Weighted Average Probability of Liquidity Event [Member]
Derivative Liability, Measurement Input	0.23
Deerfield Warrant Liability [Member] | Weighted Average Probability of Fundamental Change [Member]
Derivative Liability, Measurement Input	0.28
Embedded Put Option [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 22,000	25,000
Liabilities, Fair Value Disclosure, Increase from Ten Percent Increase in Enterprise Value	4,000
Fair Value, Inputs, Level 3 [Member] | The 2019 Notes [Member]
Long-term Debt, Fair Value		56,200,000
Fair Value, Inputs, Level 3 [Member] | January 2020 Note [Member]
Long-term Debt, Fair Value	$ 0	3,100,000
Fair Value, Inputs, Level 3 [Member] | Deerfield Facility Agreement [Member] | Deerfield Convertible Notes [Member]
Long-term Debt, Fair Value		$ 7,300,000

Note H - Fair Value of Financ_4

Note H - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Recurring [Member]
Financial liabilities measured at fair value on recurring basis		$ 304,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis		49,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis		255,000
Deerfield Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	$ 339,000	230,000
Deerfield Warrant Liability [Member] | Fair Value, Recurring [Member]
Financial liabilities measured at fair value on recurring basis	339,000	230,000
Deerfield Warrant Liability [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
Deerfield Warrant Liability [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
Deerfield Warrant Liability [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	339,000	230,000
Embedded Put Option [Member]
Financial liabilities measured at fair value on recurring basis	22,000	25,000
Embedded Put Option [Member] | Fair Value, Recurring [Member]
Financial liabilities measured at fair value on recurring basis	22,000	25,000
Embedded Put Option [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
Embedded Put Option [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
Embedded Put Option [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	22,000	25,000
KVK Warrant Liability [Member] | Fair Value, Recurring [Member]
Financial liabilities measured at fair value on recurring basis	35,000	49,000
KVK Warrant Liability [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
KVK Warrant Liability [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	35,000	49,000
KVK Warrant Liability [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
Embedded Deerfield Note Put Option [Member] | Fair Value, Recurring [Member]
Financial liabilities measured at fair value on recurring basis		0
Embedded Deerfield Note Put Option [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis		0
Embedded Deerfield Note Put Option [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis		0
Embedded Deerfield Note Put Option [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis		$ 0
Optional Exchange Principal Amount Conversion Feature [Member[ | Fair Value, Recurring [Member]
Financial liabilities measured at fair value on recurring basis	396,000
Optional Exchange Principal Amount Conversion Feature [Member[ | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis	0
Optional Exchange Principal Amount Conversion Feature [Member[ | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	35,000
Optional Exchange Principal Amount Conversion Feature [Member[ | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	$ 361,000

Note H - Fair Value of Financ_5

Note H - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Balance as of beginning of period	$ 666	$ 38	$ 255	$ 96
Adjustment to fair value	(305)	115	106	57
Balance as of end of period	$ 361	$ 153	$ 361	$ 153

Note I - Net Loss Per Share - A

Note I - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive securities (in shares)	5,270,537	1,234,913	5,390,729	1,234,913
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	0	79,748	0	79,748
January 2020 Note [Member]
Antidilutive securities (in shares)	0	34,037	0	34,037
The 2019 Notes [Member]
Antidilutive securities (in shares)	0	615,307	0	615,307
Share-based Payment Arrangement [Member]
Antidilutive securities (in shares)	1,169,379	354,379	1,169,379	354,379
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	4,101,158	151,442	4,221,350	151,442

Note I - Net Loss Per Share - E

Note I - Net Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Net income (loss)	$ (1,759)	$ 6,203	$ (10,296)	$ (3,009)	$ 859	$ (5,754)	$ (5,852)	$ (7,904)
Less: Net loss attributable to participating securities	0			0			0	0
Undistributed net income (loss), basic	$ (1,759)			$ (3,009)			$ (5,852)	$ (7,904)
Weighted average number of shares of common stock outstanding, basic (in shares)	35,217,953			4,425,474			27,904,711	3,794,840
Basic net income (loss) per share of common stock (in dollars per share)	$ (0.05)			$ (0.68)			$ (0.21)	$ (2.08)
Net income (loss)	$ (1,759)	$ 6,203	$ (10,296)	$ (3,009)	$ 859	$ (5,754)	$ (5,852)	$ (7,904)
Less: Dividends declared or accumulated	0			0			(54,342)	0
Net (loss) income attributable to common stockholders	(1,759)			(3,009)			(60,194)	(7,904)
Undistributed net (loss) income attributable to common stockholders, basic	$ (1,759)			$ (3,009)			$ (60,194)	$ (7,904)
Basic net (loss) income attributable to common stockholders per share of common stock (in dollars per share)	$ (0.05)			$ (0.68)			$ (2.16)	$ (2.08)
Less: Fair value adjustment income related to embedded Warrant Put Option	$ (16)			$ 0			$ 0	$ 0
Undistributed net loss attributable to common stockholders, diluted	$ (2,092)			$ (3,009)			$ (60,208)	$ (7,904)
Dilutive effect of awards under equity incentive plans (in shares)	0			0			0	0
Weighted average number of shares of common stock outstanding, diluted (in shares)	35,217,953			4,425,474			27,904,711	3,794,840
Diluted net loss attributable to common stockholders per share of common stock (in dollars per share)	$ (0.06)			$ (0.68)			$ (2.16)	$ (2.08)
Warrant [Member] | Deerfield Warrant [Member]
Less: Fair value adjustment income related to warrant liability	$ (290)			$ 0			$ 0	$ 0
Dilutive effect of warrant (in shares)	0			0			0	0
Warrant [Member] | KVK Warrant [Member]
Less: Fair value adjustment income related to warrant liability	$ (27)			$ 0			$ (14)	$ 0
Dilutive effect of warrant (in shares)	0			0			0	0
Warrant [Member] | Warrants to Purchase Common Stock [Member]
Dilutive effect of warrant (in shares)	0			0			0	0

Note J - Severance Expense (Det

Note J - Severance Expense (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Payment Arrangement, Expense		$ 620	$ 385	$ 1,613	$ 2,034
Severance Expense [Member]
Share-based Payment Arrangement, Expense		0	0	0	$ 420
Employee Severance [Member] | Accounts Payable and Accrued Liabilities [Member]
Accrued Severance Expense		0		0		$ 100
Employee Severance [Member] | Severance Expense [Member]
Severance Charges	$ 400	$ 0	$ 0	$ 0
Share-based Payment Arrangement, Expense	$ 400

Note K - Leases (Details Textua

Note K - Leases (Details Textual)	9 Months Ended
	Sep. 30, 2021
Lessee, Lease, Option to Extend, Maximum Term (Year)	5 years
Lessee, Lease, Option to Terminate, Term (Year)	1 year
Minimum [Member]
Lessee, Lease, Remaining Term of Contract (Year)	1 year
Maximum [Member]
Lessee, Lease, Remaining Term of Contract (Year)	4 years

Note K - Leases - Lease Cost (D

Note K - Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Amortization of right-of-use assets	$ 32	$ 31	$ 96	$ 92
Interest on lease liabilities	2	4	9	19
Total finance lease cost	34	35	105	111
Operating lease cost	91	91	274	272
Short-term lease cost	50	49	149	160
Variable lease cost	13	14	34	41
Less: sublease income	(39)	(40)	(52)	(93)
Total lease costs	$ 149	$ 149	$ 510	$ 491

Note K - Leases - Supplement Ca

Note K - Leases - Supplement Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating cash flows from finance leases	$ 9	$ 19
Financing cash flows from finance leases	156	168
Operating cash flows from operating leases	344	334
Operating cash flows from short-term leases	149	160
Operating cash flows from variable lease costs	34	41
Finance leases	0	0
Operating leases	$ 0	$ 20

Note K - Leases - Supplement Ba

Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Lease liabilities, finance leases	$ 39	$ 194
Operating lease right-of-use assets	1,186	1,350
Total operating lease right-of-use assets	1,186	1,350
Current portion of operating lease liabilities	349	327
Operating lease liabilities, less current portion	1,324	1,587
Total operating lease liabilities	$ 1,673	$ 1,914
Finance leases (years) (Year)	1 year	1 year
Operating leases (years) (Year)	4 years	5 years
Finance leases	10.50%	8.50%
Operating leases	7.50%	7.50%
Property and Equipment, At Cost [Member]
Property and equipment, at cost	$ 1,031	$ 1,031
Accumulated Depreciation and Amortization [Member]
less: accumulated depreciation and amortization	(619)	(523)
Property and Equipment, Net [Member]
Property and equipment, net	412	508
Other Current Liabilities [Member]
Other current liabilities	32	172
Other Noncurrent Liabilities [Member]
Other long-term liabilities	7	22
Operating Lease Right-of-Use Assets [Member]
Operating lease right-of-use assets	1,186	1,350
Total operating lease right-of-use assets	1,186	1,350
Current Portion of Operating Lease Liabilities [Member]
Current portion of operating lease liabilities	349	327
Operating Lease Liabilities, Less Current Portion [Member]
Operating lease liabilities, less current portion	$ 1,324	$ 1,587

Note K - Leases - Maturities of

Note K - Leases - Maturities of lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
2021 (excluding the three months ended March 31, 2021), finance leases	$ 18
2021 (excluding the three months ended March 31, 2021), operating leases	116
2022, finance leases	18
2022, operating leases	463
2023, finance leases	6
2023, operating leases	472
2024, finance leases	0
2024, operating leases	484
2025, finance leases	0
2025, operating leases	390
Thereafter, finance leases	0
Thereafter, operating leases	30
Total lease payments, finance leases	42
Total lease payments, operating leases	1,955
Less: future interest expense, finance leases	(3)
Less: future interest expense, operating leases	(282)
Lease liabilities, finance leases	39	$ 194
Lease liabilities, operating leases	$ 1,673	$ 1,914